CLL: Treatment and Management Strategies for Best Outcomes - Episode 14

An Overview of Potential Treatment Adverse Effects

June 5, 2024
Yuliya P.L Linhares, MD

,
Josie Montegaard, MSN, AGPCNP-BC

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens.

EP. 1: Understanding a CLL Diagnosis
EP. 2: Diagnostic Tests in CLL
EP. 3: Goals of Treatment for Patients With CLL
EP. 4: Current First-Line Treatment Options in CLL
EP. 5: Factors That Guide CLL Treatment Decisions
EP. 6: What to Expect from Treatment
EP. 7: Overview of Efficacy and Safety Data for Current CLL Treatment Options
EP. 8: Acalabrutinib-Based Treatment Clinical Trial Updates
EP. 9: Venetoclax-Based Treatment Clinical Trial Updates
EP. 10: Zanubrutinib-Based Treatment Clinical Trial Updates
EP. 11: Ibrutinib-Based Treatment Clinical Trial Updates
EP. 12: Newer Combinations for the Treatment of CLL
EP. 13: What to Know Before Starting Your CLL Treatment
Now Viewing
EP. 14: An Overview of Potential Treatment Adverse Effects
EP. 15: Treatment Decisions in R/R CLL
EP. 16: Shared Decision-Making and Supportive Care in the CLL Treatment Journey
EP. 17: Optimizing Overall Health During CLL Management
EP. 18: Getting the Most From Your CLL Care Team

Video content above is prompted by the following question(s):

  • What types of adverse effects may patients encounter with BTK inhibitor therapy? Venetoclax?
  • How are these adverse effects typically managed and how does a multidisciplinary team contribute to this process?
  • What guidance do you offer to patients to assist them in effective management of potential adverse events?

Related Content:

CLL: Treatment and Management Strategies for Best OutcomesBaptist Health Cancer CareDana-FarberCLLCURE Expert Connections
Understanding Treatment Sequences in Managing R/R CLL
The Pathway of Cancer is Fraught with Anxiety
Good Friends Make the Cancer Journey a Bit Easier